An antagonist of dishevelled protein-protein interaction suppresses β-catenin-dependent tumor cell growth

Cancer Research

Volumn 67, Issue 2, 2007, Pages 573-579

  Fujii, Naoaki ^a,b,e   You, Liang ^b   Xu, Zhidong ^b   Uematsu, Kazutsugu ^d   Shan, Jufang ^c   He, Biao ^b   Mikami, Iwao ^b   Edmondson, Lillian R ^a   Neale, Geoffrey ^c   Zheng, Jie ^c   Guy, R Kiplin ^a,b,e   Jablons, David M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; DISHEVELLED PROTEIN; FJ 9; FRIZZLED PROTEIN; PDZ PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BETA CATENIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; FRIZZLED RECEPTORS; HCT116 CELLS; HELA CELLS; HUMANS; INDOLES; MICE; MICE, NUDE; MODELS, MOLECULAR; PHOSPHOPROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846673934     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2726     Document Type: Article

References (50)

1. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
2. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701.
3. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
4. Mazieres J, You L, He B, et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene 2005;24:5396-400.
5. Casagrande G, te Kronnie G, Basso G. The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica 2006;91:765-71.
6. Calvo R, West J, Franklin W, et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A 2000;97:12776-81.
7. Ohira T, Gemmill RM, Ferguson K, et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A 2003;100:10429-34.
8. Winn RA, Marek L, Han SY, et al. Restoration of Wnt7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem 2005;280:19625-34.
9. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002;20:2417-28.
10. Hommura F, Furuuchi K, Yamazaki K, et al. Increased expression of β-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer 2002;94:752-8.
11. Retera JM, Leers MP, Sulzer MA, et al. The expression of β-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol 1998;51:891-4.
12. Awaya H, Takeshima Y, Amatya VJ, et al. Loss of expression of E-cadherin and β-catenin is associated with progression of pulmonary adenocarcinoma. Pathol Int 2005;55:14-8.
13. You L, He B, Uematsu K, et al. Inhibition of Wnt-1 signaling induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer Res 2004;64:3474-8.
14. Liu T, DeCostanzo AJ, Liu X, et al. G protein signaling from activated rat frizzled-1 to the β-catenin-Lef-Tcf pathway. Science 2001;292:1718-22.
15. Caricasole A, Ferraro T, Iacovelli L, et al. Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem 2003;278:37024-31.
16. Merle P, Kim M, Herrmann M, et al. Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma. J Hepatol 2005;43:854-62.
17. Vincan E, Darcy PK, Smyth MJ, et al. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation 2005;73:142-53.
18. Sagara N, Toda G, Hirai M, et al. Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun 1998;252:117-22.
19. Tanaka S, Akiyoshi T, Mori M, et al. A novel frizzled gene identified in human esophageal carcinoma mediates APC/β-catenin signals. Proc Natl Acad Sci U S A 1998;95:10164-9.
20. Wong HC, Bourdelas A, Krauss A, et al. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 2003;12:1251-60.
21. Bui TD, Beier DR, Jonssen M, et al. cDNA cloning of a human dishevelled DVL-3 gene, mapping to 3q27, and expression in human breast and colon carcinomas. Biochem Biophys Res Commun 1997;239:510-6.
22. Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of β-catenin. Cancer Res 2003;63:4547-51.
23. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-21.
24. Shan J, Shi DL, Wang J, et al. Identification of a specific inhibitor of the Dishevelled PDZ domain. Biochemistry 2005;44:15495-503.
25. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 2001;24:1-29.
26. Harris BZ, Lim WA. Mechanism and role of PDZ domains in signaling complex assembly. J Cell Sci 2001;114:3219-31.
27. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002;298:846-50.
28. Dev KK. Making protein interactions druggable: targeting PDZ domains. Nat Rev Drug Discov 2004;3:1047-56.
29. Fujii N, Haresco JJ, Novak KA, et al. A selective irreversible inhibitor targeting a PDZ protein interaction domain. J Am Chem Soc 2003;125:12074-5.
30. Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000;20:1436-47.
31. Wang CY, Guttridge DC, Mayo MW, et al. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
32. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004;6:7-14.
33. Wilson J, Rossi CP, Carboni S, et al. A homogeneous 384-well high-throughput binding assay for a TNF receptor using alphascreen technology. J Biomol Screen 2003;8:522-32.
34. London TB, Lee HJ, Shao Y, et al. Interaction between the internal motif KTXXXI of Idax and mDvl PDZ domain. Biochem Biophys Res Commun 2004;322:326-32.
35. Wharton KA, Jr. Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol 2003;253:1-17.
36. Connell ND, Rheinwald JG. Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 1983;34:245-53.
37. -/- colon carcinoma. Science 1997;275:1784-7.
38. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
39. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
40. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003;362:205-9.
41. Fukumoto S, Hsieh CM, Maemura K, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001;276:17479-83.
42. Li L, Yuan H, Xie W, et al. Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun N-terminal kinase in mammalian cells. J Biol Chem 1999;274:129-34.
43. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005;15:36-42.
44. Usami N, Sekido Y, Maeda O, et al. β-Catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion. Oncogene 2003;22:7923-30.
45. Lee AY, He B, You L, et al. Dickkopf-1 antagonizes Wnt signaling independent of β-catenin in human mesothelioma, Biochem Biophys Res Commun 2004;323:1246-50.
46. He B, Lee AY, Dadfarmay S, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells. Cancer Res 2005;65:743-8.
47. Yao R, Natsume Y, Noda T. MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap. Oncogene 2004;23:6023-30.
48. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
49. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-40.
50. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.